{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:19Z","timestamp":1790352559286,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.vaccine.2020.02.053","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T08:18:42Z","timestamp":1582618722000},"page":"2949-2959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector"],"prefix":"10.1016","volume":"38","author":[{"given":"Dylan M.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny D.","family":"Jokinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tia","family":"Pfeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Tretyakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Ricardo","family":"Carrion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pushko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor S.","family":"Lukashevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.02.053_b0005","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00705-015-2418-y","article-title":"Past, present, and future of arenavirus taxonomy","volume":"160","author":"Radoshitzky","year":"2015","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2020.02.053_b0010","unstructured":"Radoshitzky SR, Kuhn Jens H, Jahrling Peter B, Bavari Sina. Hemorrhagic Fever-Causing Mammarenaviruses. In: Bozue Joel, Cote Christopher K, Glass Pamela J, editors. Medical Aspects of Biological Warfare Published by the Office of The Surgeon General, Fort Sam Houston, Texas. 2018; Chapter 21:517-45."},{"issue":"19","key":"10.1016\/j.vaccine.2020.02.053_b0015","first-page":"1973","article-title":"WHO's Bluprint List of Priority Diseases","volume":"319","author":"Friedrich","year":"2018","journal-title":"JAMA"},{"issue":"7131","key":"10.1016\/j.vaccine.2020.02.053_b0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature05539","article-title":"Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses","volume":"446","author":"Radoshitzky","year":"2007","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.vaccine.2020.02.053_b0025","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1128\/JVI.00761-09","article-title":"Unusual molecular architecture of the machupo virus attachment glycoprotein","volume":"83","author":"Bowden","year":"2009","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2020.02.053_b0030","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.chom.2015.11.005","article-title":"Molecular basis for antibody-mediated neutralization of new world hemorrhagic fever mammarenaviruses","volume":"18","author":"Mahmutovic","year":"2015","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.053_b0035","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/s41467-019-09098-w","article-title":"Cryo-EM structure of the human ferritin-transferrin receptor 1 complex","volume":"10","author":"Montemiglio","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2020.02.053_b0040","series-title":"Vaccines for biodefense and energing and neglected diseases","first-page":"537","article-title":"Junin (Argentine Hemorrhagic Fever)","author":"McKee","year":"2009"},{"key":"10.1016\/j.vaccine.2020.02.053_b0045","series-title":"Vira hemorrhagic fevers","first-page":"317","article-title":"Argentine hemorrhagic fever","author":"Romanowski","year":"2014"},{"key":"10.1016\/j.vaccine.2020.02.053_b0050","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4269\/ajtmh.1964.13.620","article-title":"Epidemic hemorrhagic fever in Bolivia. I. A preliminary report of the epidemiologic and clinical findings in a new epidemic area in South America","volume":"13","author":"Mackenzie","year":"1964","journal-title":"Am J Trop Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2020.02.053_b0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4269\/ajtmh.1966.15.103","article-title":"Isolation of machupo virus from wild rodent calomys callosus","volume":"15","author":"Johnson","year":"1966","journal-title":"Am J Trop Med Hyg"},{"issue":"9","key":"10.1016\/j.vaccine.2020.02.053_b0060","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3201\/eid1509.090017","article-title":"Reemergence of bolivian hemorrhagic fever, 2007\u20132008","volume":"15","author":"Aguilar","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.053_b0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coviro.2014.02.007","article-title":"Epidemiology and pathogenesis of Bolivian hemorrhagic fever","volume":"5","author":"Patterson","year":"2014","journal-title":"Curr Opinion Virol"},{"key":"10.1016\/j.vaccine.2020.02.053_b0070","series-title":"Viral hemorrhagic fevers","first-page":"339","article-title":"Bolivian hemorhagic fever","author":"Radoshitzky","year":"2014"},{"key":"10.1016\/j.vaccine.2020.02.053_b0075","first-page":"240","article-title":"Junin virus vaccines","volume":"263","author":"Enria","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2020.02.053_b0080","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4269\/ajtmh.1993.48.403","article-title":"Safety and immunogenicity of a live-attenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques","volume":"48","author":"McKee","year":"1993","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"10.1016\/j.vaccine.2020.02.053_b0085","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1099\/0022-1317-78-7-1605","article-title":"Molecular characterization of attenuated Junin virus strains","volume":"78","author":"Albarino","year":"1997","journal-title":"J Gen Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2020.02.053_b0090","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11262-010-0450-2","article-title":"Molecular analysis of the virulence attenuation process in Jun\u00edn virus vaccine genealogy","volume":"40","author":"Go\u00f1i","year":"2010","journal-title":"Virus Genes"},{"issue":"19","key":"10.1016\/j.vaccine.2020.02.053_b0095","doi-asserted-by":"crossref","first-page":"10404","DOI":"10.1128\/JVI.00856-11","article-title":"The major determinant of attenuation in mice of the candid1 vaccine for argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain","volume":"85","author":"Albari\u00f1o","year":"2011","journal-title":"J Virol"},{"issue":"18","key":"10.1016\/j.vaccine.2020.02.053_b0100","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1128\/JVI.01007-14","article-title":"A substitution in the transmembrane region of the glycoprotein leads to an unstable attenuation of machupo virus","volume":"88","author":"Patterson","year":"2014","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2020.02.053_b0105","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1128\/JVI.00104-15","article-title":"The glycoprotein precursor gene of Junin virus determines the virulence of the Romero strain and the attenuation of the Candid #1 strain in a representative animal model of Argentine hemorrhagic fever","volume":"89","author":"Seregin","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.02.053_b0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fcimb.2017.00020","article-title":"Absence of an N-linked glycosylation motif in the glycoprotein of the live-attenuated argentine hemorrhagic fever vaccine, Candid #1, results in its improper processing, and reduced surface expression","volume":"7","author":"Manning","year":"2017","journal-title":"Front Cellular Infect Microbiol"},{"key":"10.1016\/j.vaccine.2020.02.053_b0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(84)90299-X","article-title":"Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma","volume":"2","author":"Enria","year":"1984","journal-title":"Lancet"},{"issue":"28(30)","key":"10.1016\/j.vaccine.2020.02.053_b0120","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1016\/j.vaccine.2010.04.077","article-title":"TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs","volume":"5","author":"Seregin","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.053_b0125","doi-asserted-by":"crossref","unstructured":"Ambrosio A, Saavedra MC, Mariani MA, Gamboa GS, AS M. Argentine hemorrhagic fever vaccines. Human Vaccines. 2011;7(6):694\u2013700.","DOI":"10.4161\/hv.7.6.15198"},{"issue":"8154","key":"10.1016\/j.vaccine.2020.02.053_b0130","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0140-6736(79)92335-3","article-title":"Efficacy of immune plasma in treatment of argentine h\u00e6morrhagic fever and association between treatment and a late neurological syndrome","volume":"314","author":"Maiztegui","year":"1979","journal-title":"The Lancet"},{"issue":"16","key":"10.1016\/j.vaccine.2020.02.053_b0135","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1073\/pnas.1600996113","article-title":"Monoclonal antibody therapy for Junin virus infection","volume":"113","author":"Zeitlin","year":"2016","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.vaccine.2020.02.053_b0140","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nsmb.1772","article-title":"Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses","volume":"17","author":"Abraham","year":"2010","journal-title":"Nat Struct Mol Biol"},{"issue":"27","key":"10.1016\/j.vaccine.2020.02.053_b0145","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1073\/pnas.1702127114","article-title":"Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization","volume":"114","author":"Zeltina","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2020.02.053_b0150","first-page":"723","article-title":"Protection of monkeys against Machupo virus by the passive administration of Bolivian haemorrhagic fever immunoglobulin (human origin)","volume":"52","author":"Eddy","year":"1975","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.053_b0155","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1038\/s41598-017-04889-x","article-title":"An attenuated Machupo virus with a disrupted L-segment intergenic region protects guinea pigs against lethal Guanarito virus infection","volume":"7","author":"Golden","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2020.02.053_b0160","first-page":"31","article-title":"Animal models for the study of rodent-borne hemorrhagic fever viruses: arenaviruses and hantaviruses","volume":"2015","author":"Golden","year":"2015","journal-title":"BioMed Res Int"},{"issue":"7","key":"10.1016\/j.vaccine.2020.02.053_b0165","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1128\/JVI.02969-15","article-title":"Glycoprotein-specific antibodies produced by DNA vaccination protect guinea pigs from lethal argentine and venezuelan hemorrhagic fever","volume":"90","author":"Golden","year":"2016","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2020.02.053_b0170","first-page":"91","article-title":"Differences in glycoprotein complex receptor binding site accessibility prompt poor cross-reactivity of neutralizing antibodies between closely related arenaviruses","author":"Brouillette","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.02.053_b0175","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.antiviral.2019.01.006","article-title":"Assessing cross-reactivity of Jun\u00edn virus-directed neutralizing antibodies","volume":"163","author":"Leske","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2020.02.053_b0180","article-title":"Monoclonal antibodies with neutralizing activity and Fc-effector functions against the Machupo virus glycoprotein","author":"Amanat","year":"2019","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2020.02.053_b0185","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1128\/JVI.02102-10","article-title":"Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic romero and live-attenuated candid #1 strains of Junin virus, the causative agent of argentine hemorrhagic fever disease","volume":"85","author":"Emonet","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2020.02.053_b0190","series-title":"Novel technologies for vaccine development","first-page":"61","article-title":"Aphavirus replicon vectors for prophylactic applications and cancer intervention","author":"Pushko","year":"2014"},{"issue":"4","key":"10.1016\/j.vaccine.2020.02.053_b0195","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2020.02.053_b0200","first-page":"1000160","article-title":"Vaccine platforms to control arenaviral hemorrhagic fevers","volume":"3","author":"Carrion","year":"2012","journal-title":"J Vacc Vaccinat"},{"issue":"5","key":"10.1016\/j.vaccine.2020.02.053_b0205","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.vaccine.2017.12.046","article-title":"Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins","volume":"36","author":"Wang","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.053_b0210","first-page":"9","article-title":"Attenuated Replication of Lassa Virus Vaccine Candidate ML29 in STAT-1(-\/-) Mice","volume":"8","author":"Johnson","year":"2019","journal-title":"Pathogens (Basel, Switzerland)"},{"issue":"12","key":"10.1016\/j.vaccine.2020.02.053_b0215","doi-asserted-by":"crossref","first-page":"e1000695","DOI":"10.1371\/journal.ppat.1000695","article-title":"A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease","volume":"5","author":"Kotturi","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2020.02.053_b0220","series-title":"Hemorrhagic fever viruses: methods and protocols","first-page":"79","article-title":"Diagnostics for lassa fever: detecting host antibody responses","author":"Salvato","year":"2018"},{"issue":"8","key":"10.1016\/j.vaccine.2020.02.053_b0225","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.vaccine.2011.12.134","article-title":"Evaluation of Lassa virus vaccine immunogenicity in a CBA\/J-ML29 mouse model","volume":"30","author":"Goicochea","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.053_b0230","doi-asserted-by":"crossref","first-page":"195-","DOI":"10.1186\/1743-422X-10-195","article-title":"A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment","volume":"10","author":"Varada","year":"2013","journal-title":"Virology journal"},{"issue":"2","key":"10.1016\/j.vaccine.2020.02.053_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056023","article-title":"Development of a neutralization assay for influenza virus using an endpoint assessment based on quantitative reverse-transcription PCR","volume":"8","author":"Teferedegne","year":"2013","journal-title":"PLoS ONE"},{"issue":"suppl 2","key":"10.1016\/j.vaccine.2020.02.053_b0240","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1093\/infdis\/jiv216","article-title":"Genetic changes at the glycoprotein editing site associated with serial passage of Sudan virus","volume":"212","author":"Alfson","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.053_b0245","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1099\/0022-1317-70-5-1125","article-title":"Junin virus monoclonal antibodies: characterization and cross-reactivity with other arenaviruses","volume":"70","author":"Sanchez","year":"1989","journal-title":"J Gen Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2020.02.053_b0250","article-title":"Machupo virus glycoprotein determinants for human transferrin receptor 1 binding and cell","volume":"6","author":"Radoshitzky","year":"2011","journal-title":"Entry PLoS One"},{"issue":"23","key":"10.1016\/j.vaccine.2020.02.053_b0255","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses","volume":"75","author":"Pushko","year":"2001","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2020.02.053_b0260","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4269\/ajtmh.2008.79.275","article-title":"Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs","volume":"79","author":"Yun","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2020.02.053_b0265","first-page":"5","article-title":"Experimental studies of arenaviral hemorrhagic fevers","volume":"134","author":"Peters","year":"1987","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.053_b0270","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/0300985815588609","article-title":"Pathogenesis of bolivian hemorrhagic fever in guinea pigs","volume":"53","author":"Bell","year":"2016","journal-title":"Veterinary Pathol"},{"issue":"6","key":"10.1016\/j.vaccine.2020.02.053_b0275","first-page":"37","article-title":"Chemotherapy for Bolivian hemorrhagic fever in experimentally infected guinea pigs","volume":"54","author":"Syromiatnikova","year":"2009","journal-title":"Vopr Virusol Russian"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.053_b0280","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12985-018-1009-4","article-title":"Description and characterization of a novel live-attenuated tri-segmented Machupo virus in Guinea pigs","volume":"15","author":"Zaza","year":"2018","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2020.02.053_b0285","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijid.2018.04.3544","article-title":"Epidemiology and virology of New World Arenaviruses","volume":"73S","author":"Sinchi","year":"2018","journal-title":"Intern J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2020.02.053_b0290","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.vaccine.2010.11.024","article-title":"Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone \u00ae in rhesus macaques","volume":"29","author":"Carroll","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2020.02.053_b0295","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/JVI.02615-15","article-title":"Machupo virus expressing GPC of the Candid#1 vaccine strain of Junin virus is highly attenuated and immunogenic","volume":"90","author":"Koma","year":"2016","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2020.02.053_b0300","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/0300985810372506","article-title":"Establishing efficacy of human products using animals","volume":"47","author":"Snoy","year":"2010","journal-title":"Veterinary Pathol"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.053_b0305","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/s41467-018-04271-z","article-title":"Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses","volume":"9","author":"Clark","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2020.02.053_b0310","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat Commun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:41:31Z","timestamp":1759401691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20302656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":62,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0264410X20302656"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.053","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}